Severe acute respiratory syndrome coronavirus 2 T-cell epitope (SARS-CoV-2 T-cell epitope)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell epitopes are specific peptide sequences derived from the viral proteome that are recognized by T lymphocytes. These epitopes are processed within host cells and presented on the cell surface by Major Histocompatibility Complex (MHC) Class I and Class II molecules to activate CD8+ cytotoxic T cells and CD4+ helper T cells, respectively. While many vaccines focus on antibody-producing B-cell epitopes on the Spike protein surface, T-cell epitopes are frequently found in more conserved internal proteins such as the Nucleocapsid and Membrane proteins, offering potential protection against diverse viral variants. In the context of drug and vaccine development, these epitopes serve as the foundational targets for T-cell-inducing vaccines and adoptive T-cell therapies aimed at providing long-lasting, cellular-mediated immunity. Monitoring T-cell responses to these epitopes is a critical biomarker for assessing natural immunity and vaccine-induced protection across human populations. Their high conservation makes them prime candidates for the development of pan-coronavirus vaccines intended to prevent future outbreaks.

Other names

SARS-CoV-2 antigenic determinantCOVID-19 T-cell epitopeSARS-CoV-2 peptide antigenSARS-CoV-2 MHC ligandSARS-CoV-2 T-lymphocyte epitope

Induction of antigen-specific CD4+ and CD8+ T-lymphocyte responses via presentation on Major Histocompatibility Complex (MHC) molecules, resulting in the elimination of virus-infected cells and the establishment of long-term immunological memory.